search
Back to results

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Primary Purpose

Epidermolysis Bullosa

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
SD-101 dermal cream (6%)
Sponsored by
Scioderm, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Epidermolysis Bullosa focused on measuring Amicus Therapeutics, Scioderm, Inc., Recessive Dystrophic, Junctional non-Herlitz, Epidermolysis Bullosa, Simplex, SD-101 6%, SD-101-6.0, Allantoin 6%, Zorblisa

Eligibility Criteria

6 Months - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Informed consent form signed by the participant or participant's legal representative; if the participant is under the age of 18 but capable of providing assent, signed assent from the participant.
  • Participant (or caretaker) must be willing to comply with all protocol requirements.
  • Participant must have successfully completed the SD-003 study.

Exclusion Criteria:

  • Participants who do not meet the inclusion criteria.
  • Pregnancy or breastfeeding during the study. A urine pregnancy test will be performed at the final visit for SD-003 for female participants of childbearing potential.
  • Females of childbearing potential who are not abstinent and not practicing a medically acceptable method of contraception.

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

SD-101 Dermal Cream (6%)

Arm Description

All participants applied SD-101 dermal cream topically, once a day, to the entire body for the duration of the study.

Outcomes

Primary Outcome Measures

Number Of Participants With Treatment-Emergent Adverse Events (TEAEs)
Treatment-emergent adverse events were defined as adverse events that started or worsened on or after baseline visit, which occurred at the final visit date for the SD-003 study. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Secondary Outcome Measures

Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 24
Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. The percentage, ranging from 0% to 100%, of affected body surface area (BSA) was recorded for each defined body region (that is, head/neck, upper limbs, trunk [includes groin], and lower limbs), multiplied by the weighting factor, and then summed for all body regions to calculate the BSAI. The BSA for lesional skin was to be assessed by the same study physician on each visit for a particular participant. The mean change from baseline (final visit from the SD-003 study) in BSAI was assessed every 3 months. Only participants with data available for analysis at the specified time point are presented.

Full Information

First Posted
March 12, 2014
Last Updated
October 31, 2019
Sponsor
Scioderm, Inc.
Collaborators
Amicus Therapeutics, Food and Drug Administration (FDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT02090283
Brief Title
Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
Official Title
An Open Label Extension, Multi-Center, Study to Evaluate the Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Terminated
Why Stopped
The Sponsor voluntarily recalled SD-101 and terminated the study due to GMP deficiencies identified during an FDA inspection at the site of the manufacturer.
Study Start Date
March 26, 2014 (Actual)
Primary Completion Date
September 14, 2018 (Actual)
Study Completion Date
September 14, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Scioderm, Inc.
Collaborators
Amicus Therapeutics, Food and Drug Administration (FDA)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study was to assess the continued safety of topical use of SD-101 cream (6%) in participants with Epidermolysis Bullosa (EB). Funding Source: FDA Office of Orphan Products Development
Detailed Description
This was an open-label extension study to assess the continued safety of topically applied SD-101 dermal cream (6%) in participants with Simplex, Recessive Dystrophic, and Junctional non-Herlitz EB. SD-101 dermal cream (6%) was applied topically, once a day to the entire body for the duration of the study. Participants who successfully completed the entire SD-003 study (NCT02014376) had the option to roll over into the SD-004 study (NCT02090283). The baseline visit occurred at the final visit date for the SD-003 study. The body surface area (BSA) coverage of blisters and lesions assessment made at the final SD-003 study visit were used as the baseline information at the baseline visit for the SD-004 study. Participants returned to the study site for the following 13 visits (36 months) to have BSA assessed. BSA was assessed at all subsequent scheduled study center visits. Scheduled study center visits occurred every 6 months after Month 36 (Month 42, 48, and so on). After completion of Month 36, the next participant visit (Month 39) was a phone call from the site to the participant. Telephone visits occurred every 6 months thereafter (Month 45, 51, and so on) and included assessment of adverse events and concomitant medications only. For female participants of childbearing potential, a urine pregnancy test was performed at Month 6 and every 6 months up to and including the final study visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epidermolysis Bullosa
Keywords
Amicus Therapeutics, Scioderm, Inc., Recessive Dystrophic, Junctional non-Herlitz, Epidermolysis Bullosa, Simplex, SD-101 6%, SD-101-6.0, Allantoin 6%, Zorblisa

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SD-101 Dermal Cream (6%)
Arm Type
Experimental
Arm Description
All participants applied SD-101 dermal cream topically, once a day, to the entire body for the duration of the study.
Intervention Type
Drug
Intervention Name(s)
SD-101 dermal cream (6%)
Other Intervention Name(s)
SD-101, SD-101-6.0, Zorblisa
Intervention Description
SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Primary Outcome Measure Information:
Title
Number Of Participants With Treatment-Emergent Adverse Events (TEAEs)
Description
Treatment-emergent adverse events were defined as adverse events that started or worsened on or after baseline visit, which occurred at the final visit date for the SD-003 study. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Time Frame
From baseline to 30 days after last application of study drug (up to a maximum of 54 months)
Secondary Outcome Measure Information:
Title
Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 24
Description
Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. The percentage, ranging from 0% to 100%, of affected body surface area (BSA) was recorded for each defined body region (that is, head/neck, upper limbs, trunk [includes groin], and lower limbs), multiplied by the weighting factor, and then summed for all body regions to calculate the BSAI. The BSA for lesional skin was to be assessed by the same study physician on each visit for a particular participant. The mean change from baseline (final visit from the SD-003 study) in BSAI was assessed every 3 months. Only participants with data available for analysis at the specified time point are presented.
Time Frame
Baseline, Month 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Informed consent form signed by the participant or participant's legal representative; if the participant is under the age of 18 but capable of providing assent, signed assent from the participant. Participant (or caretaker) must be willing to comply with all protocol requirements. Participant must have successfully completed the SD-003 study. Exclusion Criteria: Participants who do not meet the inclusion criteria. Pregnancy or breastfeeding during the study. A urine pregnancy test will be performed at the final visit for SD-003 for female participants of childbearing potential. Females of childbearing potential who are not abstinent and not practicing a medically acceptable method of contraception.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Amicus Therapeutics
Official's Role
Study Director
Facility Information:
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27516
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78218
Country
United States
City
Seattle
State/Province
Washington
ZIP/Postal Code
98105
Country
United States

12. IPD Sharing Statement

Citations:
Citation
Paller A., Browning J., Aslam R., et al. Efficacy and Safety Results From a 24-Month, Open-Label Extension of a Phase 2b Dose-Ranging Study of SD-101 Cream in Patients With Epidermolysis Bullosa. Abstract presented at European Academy of Dermatology and Venereology, 26th Congress, Geneva, Switzerland, September 13-17, 2017.
Results Reference
result

Learn more about this trial

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

We'll reach out to this number within 24 hrs